title: Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.
abstract: BACKGROUND
  Botulinum Toxin Type-A (BoNT/A) intraprostatic injection can induce prostatic involution and improve LUTS and urinary flow in patients with Benign Prostatic Enlargement (BPE). However, the duration of these effects is unknown. The objective of this work was to determine the duration of prostate volume reduction after one single intraprostatic injection of 200U of Botulinum Toxin Type-A.
  
  
  METHODS
  This is an extension of a 6 month study in which 21 frail elderly patients with refractory urinary retention and unfit for surgery were submitted to intraprostatic injection of BoNT/A-200U, by ultrasound guided transrectal approach. In spite of frail conditions, eleven patients could be followed during 18 months. Prostate volume, total serum PSA, maximal flow rate (Qmax), residual volume (PVR) and IPSS-QoL scores were determined at 1, 3, 6, 12 and 18 months post-treatment.
  
  
  RESULTS
  Mean prostate volume at baseline, 82 +/- 16 ml progressively decreased from month one coming to 49 +/- 9,5 ml (p = 0,003) at month six. From this moment on, prostate volume slowly recovered, becoming identical to baseline at 18 months (73 +/- 16 ml, p = 0.03). Albeit non significant, serum PSA showed a 25% decrease from baseline to month 6. The 11 patients resumed spontaneous voiding at month one. Mean Qmax was 11,3 +/- 1,7 ml/sec and remained unchanged during the follow-up period. PVR ranged from 55 +/- 17 to 82 +/- 20 ml and IPSS score from10 to 12 points.
  
  
  CONCLUSIONS
  Intraprostatic BoNT/A injection is safe and can reduce prostate volume for a period of 18 months. During this time a marked symptomatic improvement can be maintained.
authors.affiliation: Department of Urology, Hospital S, João, Porto, Portugal. jfalturas@gmail.com
authors.forename: João
authors.initials: J
authors.lastname: Silva
authors.forename: Rui
authors.initials: R
authors.lastname: Pinto
authors.forename: Tiago
authors.initials: T
authors.lastname: Carvalho
authors.forename: Francisco
authors.initials: F
authors.lastname: Botelho
authors.forename: Pedro
authors.initials: P
authors.lastname: Silva
authors.forename: Rui
authors.initials: R
authors.lastname: Oliveira
authors.forename: Carlos
authors.initials: C
authors.lastname: Silva
authors.forename: Francisco
authors.initials: F
authors.lastname: Cruz
authors.forename: Paulo
authors.initials: P
authors.lastname: Dinis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D019274:Botulinum Toxins, Type A
references.citation: Urology. 2005 Oct;66(4):775-9
references.pmid: 16230137
references.citation: J Urol. 2008 Oct;180(4):1314-7; discussion 1317
references.pmid: 18707733
references.citation: Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119
references.pmid: 16465187
references.citation: Neurourol Urodyn. 2007 Oct;26(6 Suppl):920-7
references.pmid: 17705161
references.citation: BMC Urol. 2006 Apr 18;6:12
references.pmid: 16620393
references.citation: Urology. 2009 Jan;73(1):90-4
references.pmid: 18995889
references.citation: Toxicon. 2009 Oct;54(5):668-74
references.pmid: 19470342
references.citation: Prostate. 1998 Sep 15;37(1):44-50
references.pmid: 9721068
references.citation: Urology. 2005 Apr;65(4):670-4
references.pmid: 15833506
references.citation: Scand J Urol Nephrol. 2009;43(3):206-11
references.pmid: 19308807
references.citation: Eur Urol. 2008 Jan;53(1):153-9
references.pmid: 17825981
references.citation: Eur Urol. 2009 Jul;56(1):134-40
references.pmid: 18649990
references.citation: BJU Int. 2006 Nov;98(5):1033-7; discussion 1337
references.pmid: 16956361
references.citation: Yonsei Med J. 2006 Oct 31;47(5):706-14
references.pmid: 17066515
references.citation: Eur Urol. 2008 Aug;54(2):326-34
references.pmid: 18160204
references.citation: Eur Urol. 2007 Aug;52(2):582-9
references.pmid: 17386969
references.citation: Urology. 2003 Aug;62(2):259-64; discussion 264-5
references.pmid: 12893330
references.citation: Urology. 2001 Dec;58(6 Suppl 1):65-70; discussion 70
references.pmid: 11750255
references.citation: Eur Urol. 2008 Oct;54(4):765-75
references.pmid: 18571306
references.citation: Urology. 2001 Dec;58(6 Suppl 1):25-32; discussion 32
references.pmid: 11750246